1
|
Francoual J, Lebreton G, Bazille C, Galais MP, Dupont B, Alves A, Lubrano J, Morello R, Menahem B. Is pathological complete response after a trimodality therapy, a predictive factor of long-term survival in locally-advanced esophageal cancer? Results of a retrospective monocentric study. J Visc Surg 2018; 155:365-374. [PMID: 29501383 DOI: 10.1016/j.jviscsurg.2018.02.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To evaluate long-term (5- and 10-year) survival and recurrence rates on the basis of the pathological complete response (pCR) in the specimens of patients with esophageal carcinoma, treated with trimodality therapy. METHODS Between 1993 and 2014, all consecutives patients with esophageal locally-advanced non-metastatic squamous cell carcinoma (SCC) or adenocarcinoma (ADC) who received trimodality therapy were reviewed. According to histopathological analysis, patients were divided in two groups with pCR and with pathological residual tumor (pRT). The primary endpoint was overall survival (OS). The secondary endpoints included the disease-free survival (DFS), the recurrence rate, and the predictive factors of overall survival and recurrence. RESULTS One hundred and three patients were included: 49 patients with pCR and 54 patients with pRT. The median OS was significantly longer in pCR group than in pRT group (132±22.3 vs. 25.5±4 months), with both 5- and 10-years OS rates of 75.2% vs. 29.1%, and 51.1% vs. 13.6%, respectively (P<0.001). Also, pRT, major postoperative complications (Dindo-Clavien grade>IIIb) and recurrence were the 3 independent predictive factors for worse OS. CONCLUSIONS Patients with locally-advanced oesophageal carcinoma, who responded to trimodality therapy with a pCR, could be achieved a 10-year survival rate of 51%.
Collapse
Affiliation(s)
- J Francoual
- Department of digestive surgery, University Hospital of Caen, avenue de la Côte-de-Nacre, 14033 Caen cedex, France.
| | - G Lebreton
- Department of digestive surgery, University Hospital of Caen, avenue de la Côte-de-Nacre, 14033 Caen cedex, France
| | - C Bazille
- Department of histopathology, University Hospital of Caen, avenue de la Côte-de-Nacre, 14033 Caen cedex, France
| | - M P Galais
- Department of oncology and radiotherapy, University Hospital of Caen, avenue de la Côte-de-Nacre, 14033 Caen cedex, France
| | - B Dupont
- Department of hepatogastroenterology, University Hospital of Caen, avenue de la Côte-de-Nacre, 14033 Caen cedex, France
| | - A Alves
- Department of digestive surgery, University Hospital of Caen, avenue de la Côte-de-Nacre, 14033 Caen cedex, France; Inserm UMR 1086, UNICAEN, CEA, CNRS, Centre François Baclesse, CHU de Caen, Normandie University, 3, avenue du Général-Harris, 14045 Caen cedex, France
| | - J Lubrano
- Department of digestive surgery, University Hospital of Caen, avenue de la Côte-de-Nacre, 14033 Caen cedex, France; Inserm UMR 1086, UNICAEN, CEA, CNRS, Centre François Baclesse, CHU de Caen, Normandie University, 3, avenue du Général-Harris, 14045 Caen cedex, France
| | - R Morello
- Department of biostatistical, Centre Georges-Clemenceau, University Hospital of Caen, 14000 Caen cedex, France
| | - B Menahem
- Department of digestive surgery, University Hospital of Caen, avenue de la Côte-de-Nacre, 14033 Caen cedex, France; Inserm UMR 1086, UNICAEN, CEA, CNRS, Centre François Baclesse, CHU de Caen, Normandie University, 3, avenue du Général-Harris, 14045 Caen cedex, France
| |
Collapse
|